Role of EGFR, HER2 and PIK3CA alterations in male breast cancer

被引：0
|
作者：
Rizzolo, P. [1 ]
Silvestri, V. [1 ]
Falchetti, M. [1 ]
Zanna, I. [2 ]
Palli, D. [2 ]
Ottini, L. [1 ]
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] Canc Prevent & Res Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 05期
关键词：
D O I：
10.1016/S1359-6349(10)70901-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [1] PIK3CA alterations in metastatic breast cancer (mBC)
    Albanell, J.
    Casadevall, D.
    Sokol, E. S.
    Albacker, L. A.
    Elvin, J. A.
    Vergilio, J-A.
    Killian, J. K.
    Ngo, N.
    Lin, D.
    Ramkissoon, S.
    Severson, E.
    Ali, S. M.
    Schrock, A. B.
    Chung, J.
    Reddy, P.
    Miller, V. A.
    Alexander, B. M.
    McGregor, K.
    Ross, J. S.
    Leyland-Jones, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 104 - +
  • [2] LAPATINIB IN BREAST CANCER - THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT
    Bouchalova, Katerina
    Cizkova, Magdalena
    Cwiertka, Karel
    Trojanec, Radek
    Friedecky, David
    Hajduch, Marian
    [J]. BIOMEDICAL PAPERS-OLOMOUC, 2010, 154 (04): : 281 - 288
  • [3] PIK3CA and EGFR mutation in triple negative breast carcinoma: Comparison with hormone receptors positive and HER2 positive breast carcinomas
    Pestereli, H. E.
    Ozcan, M.
    Erdogan, G.
    Karaveli, F. S.
    [J]. VIRCHOWS ARCHIV, 2013, 463 (02) : 248 - 248
  • [4] HER2, EGFR, PIK3CA mutations in HER2+metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
    Gori, S.
    Ludovini, V.
    Colozza, M.
    Pistola, L.
    Tofanetti, F. R.
    Flacco, A.
    Foglietta, J.
    Minenza, E.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] The unexpected role of p110β in HER2 amplified and PIK3CA mutant breast cancers.
    Costa, Carlotta
    Ebi, Hiromichi
    Faber, Anthony C.
    Nishtala, Madhuri
    Song, Young Chul
    Engelman, Jeffrey A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [6] Significance of EGFR/HER2 Expression and PIK3CA Mutations in Giant Cell Tumour of Bone Development
    Amri, Raja
    Charfi, Slim
    Jema, Mohamed
    Miled, Nabil
    Slimi, Fathia
    Rebai, Mohamed Ali
    Abdelwahed, Mayssa
    Keskes, Hassib
    Aifa, Sami
    [J]. BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [7] Role of ddPCR in the diagnosis of PIK3CA in breast cancer
    Grudeva-Popova, Z.
    Raicheva, G.
    Ivanov, H.
    Stojanova, V.
    Linev, A.
    Jeljazkov, I.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S496 - S496
  • [8] Overexpression of PIK3CA impacts global survival of patients with HER2 subtype breast carcinoma
    Felicidade, Sidnei Iensen
    Salles Pilar, Emily Ferreira
    Flores Texeira, Joara Predebom
    Watte, Guilherme
    Remonatto, Gabriela
    Sant'Anna Alves, Rita de Cassia
    Roehe, Adriana Vial
    [J]. JOURNAL OF BUON, 2020, 25 (06): : 2546 - 2551
  • [9] Analysis of PIK3CA mutation abundance in primary breast cancer with droplet digital PCR identifies frequent sub-clonal PIK3CA mutations in ER negative and/or HER2 positive breast cancer
    Garcia-Murillas, I.
    Pearson, A.
    Lambros, M.
    Natrajan, R.
    Segal, C.
    Dowsett, M.
    Turner, N. C.
    [J]. CANCER RESEARCH, 2013, 73
  • [10] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
12345